• View Press Releases

    View Press Releases

News & Media

Recent News

Seattle Genetics Announces Additional Clinical Collaborations to Evaluate SGN-LIV1A in Triple Negative Breast Cancer More

Seattle Genetics and Astellas Initiate Pivotal Trial of Enfortumab Vedotin for Patients with Locally Advanced or Metastatic Urothelial Cancer More

Genmab and Seattle Genetics to Initiate New Study of Novel Antibody-Drug Conjugate Tisotumab Vedotin in Cervical Cancer More

View All News

Quick Facts

Year founded 1998

Nasdaq SGEN

Number of Employees 1,000+

Global Headquarters Bothell, WA

European Headquarters Zug, Switzerland

icon-sw.png

Primary Product ADCETRIS® (brentuximab vedotin)

adcetris.png

Disease Focus Areas Hodgkin lymphoma, non-Hodgkin lymphoma, urothelial cancer, breast cancer, acute myeloid leukemia

heart.png

Clinical & preclinical pipeline programs 12+

ADCs in clinical trials using our technology 20+

Resources

Social Media

 

Media Contacts

For Media Professionals Only

Brandi Robinson

Sr. VP, Corporate Communications

media@seagen.com